Intellectual Property India Publishes Patent Application for Use Of Melanocortin-4 Receptor Agonists For The Treatment Of A Lepr And/Or Sh2b1 Deficiency

MUMBAI, India, Oct. 19 -- Intellectual Property India has published a patent application (202617089656 A) filed by Lg Chem, Ltd.; Rhythm Pharmaceuticals, Inc.; Park, Hee, Dong; and Hwang, Hye, Kyeong on July 23, 2026, for Use Of Melanocortin-4 Receptor Agonists For The Treatment Of A Lepr And/Or Sh2b1 Deficiency.

Inventors include Park, Hee, Dong; and Hwang, Hye, Kyeong.

The application for the patent was published on October 16, 2026, under issue no. 42/2026.

Abstract: The present disclosure relates to the use of a compound of chemical Formula 1 or a pharmaceutically acceptable salt thereof for the purpose of preventing, improving, or treating a genetic obesity disease associated with the melanocortin-4 receptor (MC4R) pathway, particul...